Real Estate [ 10/12 ] | Diversified REITs [ 61/74 ]
NYSE | Common Stock
Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500® company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world.
As the pioneer of the life science real estate niche since our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative life science mega campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City.
Alexandria has a total market capitalization of 34.4 billion and an asset base in North America of 74.1 million SF as of March 31, 2024, which includes 42.2 million RSF of operating properties, 5.3 million RSF of Class A/A+ properties undergoing construction and one committed near-term project expected to commence construction in the next two years, 2.5 million RSF of priority anticipated development and redevelopment projects, and 24.1 million SF of future development projects.
Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in life science mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success.
Alexandria also provides strategic capital to transformative life science companies through our venture capital platform.
We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.
Reported date | EPSChange YoY | EstimateSurprise |
---|---|---|
Oct 21, 24 | 0.96 Increased by +638.46% | 0.90 Increased by +6.67% |
Jul 22, 24 | 0.25 Decreased by -50.98% | 0.80 Decreased by -68.75% |
Apr 22, 24 | 0.97 Increased by +120.45% | 0.81 Increased by +19.75% |
Jan 29, 24 | -0.54 Decreased by -274.19% | 0.56 Decreased by -196.43% |
Oct 23, 23 | 0.13 Decreased by -93.84% | 1.14 Decreased by -88.60% |
Jul 24, 23 | 0.51 Decreased by -69.46% | 0.64 Decreased by -20.31% |
Apr 24, 23 | 0.44 Increased by +145.83% | 0.78 Decreased by -43.59% |
Jan 30, 23 | 0.31 Decreased by -34.04% | 0.69 Decreased by -55.07% |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 24 | 775.74 M Increased by +8.68% | 164.67 M Increased by +578.54% | Increased by +21.23% Increased by +524.34% |
Jun 30, 24 | 766.73 M Increased by +7.40% | 46.70 M Increased by +179.69% | Increased by +6.09% Increased by +160.41% |
Mar 31, 24 | 769.11 M Increased by +9.75% | 170.54 M Increased by +420.73% | Increased by +22.17% Increased by +374.48% |
Dec 31, 23 | 757.22 M Increased by +12.97% | 391.19 M Increased by +403.16% | Increased by +51.66% Increased by +345.40% |
Sep 30, 23 | 713.79 M Increased by +8.17% | 24.27 M Decreased by -92.96% | Increased by +3.40% Decreased by -93.49% |
Jun 30, 23 | 713.90 M Increased by +10.89% | 16.70 M Decreased by -93.87% | Increased by +2.34% Decreased by -94.47% |
Mar 31, 23 | 700.79 M Increased by +13.94% | 32.75 M Increased by +121.90% | Increased by +4.67% Increased by +119.22% |
Dec 31, 22 | 670.28 M Increased by +16.18% | 77.75 M Increased by +3.81% | Increased by +11.60% Decreased by -10.65% |